Skip to main content

Month: August 2025

Bath & Body Works to Report Second Quarter Results on August 28, 2025

COLUMBUS, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) — Bath & Body Works, Inc. (NYSE: BBWI) announced today that it plans to report its second quarter 2025 financial results before market open on Thursday, August 28, 2025. In conjunction with this report, the company will host a conference call at 8:30 a.m. ET during which Daniel Heaf, chief executive officer, and Eva Boratto, chief financial officer, will discuss the company’s results and provide a business update. Supplemental materials will be posted approximately 90 minutes prior to the start of the conference call on the events and presentations page in the Investors section of the company’s website at bbwinc.com. Investors and analysts interested in participating in the conference call are invited to dial 877-407-9219 (domestic) or 412-652-1274 (international). A telephone...

Continue reading

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We believe we are at an inflection point in Adial’s journey. With the successful completion of our End of Phase 2 meeting with the Food and Drug Administration (FDA), we have received critical input from the FDA on the clinical and statistical design of our upcoming Phase 3 trial for AD04, our lead investigational drug and a serotonin-3 receptor antagonist being developed for the treatment of Alcohol Use Disorder...

Continue reading

Vivid Seats Unveils 2025 NFL Fan Loyalty Report

Eagles Claim Top Spot for Road Support, Cowboys Reign in National Footprint, Raiders Fans Travel the Farthest CHICAGO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT), a leading marketplace that connects fans to live events, today released its 2025 NFL Fan Loyalty Report*, highlighting the most dedicated fanbases ahead of the upcoming 2025-26 season. Drawing from its proprietary data, Vivid Seats analyzed fan behavior across three key metrics: travel, crowd presence, and year-over-year price increases. The result is a snapshot of which teams are inspiring the strongest fan support heading into the new season.  Road Warriors: Eagles Soar to No. 1 Vivid Seats’ Fan Forecast® projects which fanbases dominate the stands each week. By analyzing trends from the 2024 NFL regular season, Vivid Seats identified the fanbases...

Continue reading

ECD Automotive Strengthens Balance Sheet Through $10 Million Debt-for-Equity Exchange and Completes a $999,900 Equity Raise

KISSIMMEE, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (NASDAQ: ECDA) (“ECD” or the “Company”), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs and Toyota FJs, announced that it has exchanged $10 million of outstanding convertible promissory notes for 15,000 newly issued shares of ECD’s Series C Convertible Preferred Stock. In addition, the Company has completed a private placement of the sale of 1,111 shares of the Company’s Series C Convertible Preferred Stock in exchange for $999,900. These transactions represent significant steps toward fortifying ECD’s capital structure and advancing the Company’s plan to regain compliance with Nasdaq listing standards. The exchange materially deleverages...

Continue reading

Respected VMS Expert, Economic Geologist Dr. Stephen Piercey Joins Callinex’s Technical Team

Highlights:Dr. Stephen Piercey, P. Geo., is an exploration and economic geologist with over 25 years experience focused on VMS deposits;  He has received numerous awards for his work including the D. R. Derry Medal, the highest award bestowed by the Mineral Deposits Division of the Geological Association of Canada; and Will provide oversight in the next stages of exploration as the Company is set to utilize a modern integrated exploration approach to drive resource growth at the Pt. Leamington project. VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Callinex Mines Inc. (the “Company” or “Callinex”) (TSX-V: CNX; OTCQX: CLLXF) is pleased to announce that it has appointed Professional Geologist and exploration consultant, Stephen Piercey, PhD, P.Geo., FGC, to the Company’s technical team. Dr. Piercey is an award-winning...

Continue reading

DTST Reports 2025 Second Quarter Financial Results and Provides Business Update

Conference Call to be Held Today at 11:00 am ET MELVILLE, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (the “Company”), today provided a business update and reported financial results for the three months and six months ended June 30, 2025. Second Quarter 2025 Highlights:Revenue was $5.1 million, up 4.8% from the same period in 2024, driven by continued growth in subscription-based cloud and Nexxis services Gross profit totaled $2.5 million, maintaining consistent margin levels Cash and marketable securities were $11.1 million, with no long term debt“We continue to see strong growth in our core business, particularly in our higher-margin, recurring subscription sales,” said Chuck Piluso, Chairman and Chief Executive Officer of Data Storage Corporation. “Building on this momentum, a central...

Continue reading

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women’s Hospital in Boston, Massachusetts. MSA is a rare, rapidly progressive neurodegenerative disorder affecting the body’s movement, balance, and autonomic functions. Classified as an orphan disease by the FDA, MSA affects an estimated 15,000–50,000 people in the United States. There are no FDA-approved treatments that alter its course, creating...

Continue reading

Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA

Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission. We are now focused on addressing the items we received in the FDA letter and will have an initial call with the FDA within 10 days as provided in the FDA correspondence. We also intend to participate in a pre-sub meeting with the FDA review team in the coming weeks, with the goal of resubmitting the application for the IDE. Radiogel® received the FDA Breakthrough Device Designation and has demonstrated an unparalleled therapeutic ratio and strong safety profile. Vivos remains committed to pursuing approval for Radiogel® in the US market. Michael K. Korenko, Sc.D.President & CEO, Vivos Inc.Email: MKorenko@RadioGel.comFollow Vivos Inc. on X (Twitter): @VivosIncUSALearn...

Continue reading

Fluent, Inc. Adds Authentic Brands Group to Partner Network, Powering Post-Purchase Monetization Across Brand Portfolio

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leader in commerce media, today announced an expanded partnership with Authentic Brands Group (Authentic), bringing a portfolio of iconic brands into Fluent’s growing network of commerce media partners – further reinforcing its position as a trusted post-purchase monetization partner to leading retailers. Authentic is the world’s leading sports, lifestyle, and entertainment brand owner, with a portfolio that generates more than $32 billion in global annual retail sales. The partnership follows successful campaign launches across several of Authentic’s owned and licensed brands, including Eddie Bauer, Nautica, Lucky Brand and Aéropostale. Now, through a broader agreement, Fluent will support post-purchase monetization for additional brands such as Reebok,...

Continue reading

SOLOWIN Unveils Real Yield Token (RYT), Targeting US$1 Billion AUM

Collaborate with Polygon, Arbitrum and Solana to deliver scalable blockchain infrastructure for regulated tokenized yield product HONG KONG, Aug. 14, 2025 (GLOBE NEWSWIRE) — via IBN — SOLOWIN HOLDINGS (NASDAQ: SWIN) (“Solowin” or the “Company”), a leading financial services firm providing comprehensive solutions across traditional and digital assets, today announced its initiative to achieve US$1 billion in assets under management (AUM) for its USD Money Market Real Yield Token (RYT) by the end of 2025. Launched on April 15, 2025, RYT is offered through the Company’s wholly-owned subsidiary, Solomon JFZ (Asia) Holdings Limited (“Solomon”), in collaboration with Standard Chartered, China Asset Management (Hong Kong) (“China AMC (HK)”), Libeara and AlloyX Limited (“AlloyX”). The initiative’s US$1 billion AUM target also supported...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.